ZA200705160B - Quinoline derivatives for the treatment of latent tuberculosis - Google Patents

Quinoline derivatives for the treatment of latent tuberculosis

Info

Publication number
ZA200705160B
ZA200705160B ZA200705160A ZA200705160A ZA200705160B ZA 200705160 B ZA200705160 B ZA 200705160B ZA 200705160 A ZA200705160 A ZA 200705160A ZA 200705160 A ZA200705160 A ZA 200705160A ZA 200705160 B ZA200705160 B ZA 200705160B
Authority
ZA
South Africa
Prior art keywords
treatment
quinoline derivatives
latent tuberculosis
tuberculosis
latent
Prior art date
Application number
ZA200705160A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200705160B publication Critical patent/ZA200705160B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200705160A 2004-12-24 2007-06-22 Quinoline derivatives for the treatment of latent tuberculosis ZA200705160B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24

Publications (1)

Publication Number Publication Date
ZA200705160B true ZA200705160B (en) 2008-09-25

Family

ID=36736133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705160A ZA200705160B (en) 2004-12-24 2007-06-22 Quinoline derivatives for the treatment of latent tuberculosis

Country Status (9)

Country Link
JP (5) JP2006182755A (ja)
KR (2) KR101301573B1 (ja)
CN (1) CN101087608A (ja)
BG (1) BG66437B1 (ja)
EA (1) EA009779B1 (ja)
ES (1) ES2362886T3 (ja)
JO (1) JO2695B1 (ja)
UA (1) UA88766C2 (ja)
ZA (1) ZA200705160B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
CN103664877A (zh) * 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
BR122021024097B1 (pt) * 2016-03-07 2024-04-30 The Global Alliance For Tb Drug Development, Inc Composto antibacteriano, uso do mesmo e composição farmacêutica
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
UA82198C2 (uk) * 2002-07-25 2008-03-25 Янссен Фармацевтика Н.В. Хінолінові похідні та їх використання як мікобактеріальних інгібіторів, спосіб їх одержання, фармацевтична композиція на їх основі, проміжна сполука
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases

Also Published As

Publication number Publication date
ES2362886T3 (es) 2011-07-14
KR20130041872A (ko) 2013-04-25
EA200500802A1 (ru) 2006-06-30
JP2006182755A (ja) 2006-07-13
BG66437B1 (bg) 2014-07-31
JP6426530B2 (ja) 2018-11-21
KR101301573B1 (ko) 2013-09-04
BG109180A (bg) 2006-06-30
JP2017141259A (ja) 2017-08-17
KR20060073416A (ko) 2006-06-28
JP2013049704A (ja) 2013-03-14
EA009779B1 (ru) 2008-04-28
JO2695B1 (en) 2013-03-03
CN101087608A (zh) 2007-12-12
UA88766C2 (ru) 2009-11-25
JP2017141262A (ja) 2017-08-17
JP2015157847A (ja) 2015-09-03

Similar Documents

Publication Publication Date Title
HK1186125A1 (en) Quinoline derivatives for the treatment of latent tuberculosis
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
HK1104235A1 (en) S-mirtazapine for the treatment of hot flush
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
ZA200800921B (en) Pyrazolone derivatives for the treatment of tuberculosis
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0408297D0 (en) Indole derivatives for the treatment of diseases
GB0412299D0 (en) Method for the synthesis of halogenated heterocycles
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
HK1096379A1 (en) Sulfonamide derivatives for the treatment of diseases